The U.S. Department of Health and Human Services (HHS) has awarded $1.4 billion to support vaccine clinical trials to test new, more effective and longer-lasting COVID-19 vaccines. In all, Project NextGen is a $5 billion initiative from Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). The…
Baricitinib shows promise in reducing COVID-19 lung infection in study
Olumiant (baricitinib), an anti-inflammatory medication from Eli Lilly (NYSE:LLY), is effective for reducing lung inflammation in COVID-19 patients when administered early after infection, according to a peer-reviewed study published in Cell. A NIAID-backed clinical trial known as the Adaptive COVID-19 Treatment Trial (ACTT-4) is testing baricitinib alongside the common steroid dexamethasone. The trial began in November. A related trial, ACTT-2,…